🏅 FDA Orphan Designation
Sucraid
Sacrosidase
Manufacturer: QOL Medical, LLC
Indicated for:
FDA-Approved Indications (1)
Congenital sucrase-isomaltase deficiencyOrphan Designation
Oral replacement therapy of the genetically determined sucrase deficiency, which is part of congenital sucrease-isomaltase deficiency.
Indications & Usage
INDICATIONS AND USAGE Sucraid ® (sacrosidase) Oral Solution is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older.
💙 Support Programs
View all →Sucraid
QOL Medical, LLC
Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.
Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.